is think about ced statistically significant improvements in FPG and HbA1c compared to baseline and relative to placebo. Data from one of these studies are summarized in Table 9. Table 9. Glycemic Parameters in a 26-Week Placebo-Controlled Trial Placebo Rosiglitazone maleate Rosiglitazone maleate 4 mg once daily 2 mg twice daily 8 mg once daily 4 mg twice daily N = 173 N = 180 N = 186 N = 181 N = 187 FPG (mg/dL) Baseline (mean) 225 229 225 228 228 Change from baseline (mean) 8 -25 -35 -42 -55 Difference from placebo (adjusted mean) -31 * -43 * -49 * -62 * % of patients with 30 mg/dL decrease from baseline 19% 45% 54% 58% 70% HbA1c (%) Baseline (mean) 8.9 8.9 8.9 8.9 9.0 Change from baseline (mean) 0.8 0.0 -0.1 -0.3 -0.7 Difference from placebo (adjusted mean) -0.8 * -0.9 * -1.1 * -1.5 * % of patients with 0.7% decrease from baseline 9% 28% 29% 39% 54% * p <0.0001 compared to placebo. When administered at the same total daily dose costs
Photo :ced statistically significant improvements in FPG and HbA1c compared to baseline and relative to placebo. Data from one of these studies are summarized in Table 9. Table 9. Glycemic Parameters in a 26-Week Placebo-Controlled Trial Placebo Rosiglitazone maleate Rosiglitazone maleate 4 mg once daily 2 mg twice daily 8 mg once daily 4 mg twice daily N = 173 N = 180 N = 186 N = 181 N = 187 FPG (mg/dL) Baseline (mean) 225 229 225 228 228 Change from baseline (mean) 8 -25 -35 -42 -55 Difference from placebo (adjusted mean) -31 * -43 * -49 * -62 * % of patients with 30 mg/dL decrease from baseline 19% 45% 54% 58% 70% HbA1c (%) Baseline (mean) 8.9 8.9 8.9 8.9 9.0 Change from baseline (mean) 0.8 0.0 -0.1 -0.3 -0.7 Difference from placebo (adjusted mean) -0.8 * -0.9 * -1.1 * -1.5 * % of patients with 0.7% decrease from baseline 9% 28% 29% 39% 54% * p <0.0001 compared to placebo. When administered at the same total daily dose without notice Rosiglitazone maleate was generally more effective in reducing FPG and HbA1c when administered in divided doses twice daily compared to once daily doses. However most suitable
potential ced statistically significant improvements in FPG and HbA1c compared to baseline and relative to placebo. Data from one of these studies are summarized in Table 9. Table 9. Glycemic Parameters in a 26-Week Placebo-Controlled Trial Placebo Rosiglitazone maleate Rosiglitazone maleate 4 mg once daily 2 mg twice daily 8 mg once daily 4 mg twice daily N = 173 N = 180 N = 186 N = 181 N = 187 FPG (mg/dL) Baseline (mean) 225 229 225 228 228 Change from baseline (mean) 8 -25 -35 -42 -55 Difference from placebo (adjusted mean) -31 * -43 * -49 * -62 * % of patients with 30 mg/dL decrease from baseline 19% 45% 54% 58% 70% HbA1c (%) Baseline (mean) 8.9 8.9 8.9 8.9 9.0 Change from baseline (mean) 0.8 0.0 -0.1 -0.3 -0.7 Difference from placebo (adjusted mean) -0.8 * -0.9 * -1.1 * -1.5 * % of patients with 0.7% decrease from baseline 9% 28% 29% 39% 54% * p <0.0001 compared to placebo. When administered at the same total daily dose from time to time
EmoticonEmoticon